"uuid:ID","id","versionIdentifier","instanceType","rationale"
"cebc5ba1-10de-4be8-a49b-6bcfe44dc73a","StudyVersion_1","2","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
